Skip to content

Study of the Sexual Health of Patients Treated for Breast Cancer and Followed up in the Observatory of Fertility at Jeanne de Flandre Hospital.

Study of the Sexual Health of Patients Treated for Non-metastatic Breast Cancer and Followed up in the Observatory of Fertility at Jeanne de Flandre Hospital : a Prospective Monocentric Cohort With Repeated Anonymous Self-administered Questionnaires.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04852926
Acronym
ENVIE
Enrollment
25
Registered
2021-04-21
Start date
2021-07-13
Completion date
2025-06-13
Last updated
2025-12-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Breast Carcinoma, Breast Neoplasms, Breast Tumor

Keywords

Breast cancer, Fertility preservation Quality of life Sexual health Marital satisfaction, Quality of life, Sexual health, Marital satisfaction

Brief summary

Study of sexual health by repeated anonymous self-administered questionnaires in patients treated for non-metastatic breast cancer and referred to Jeanne de Flandre hospital for possible preservation of their fertility. Sexual health is affected by treatments and improves after the treatments. Sexual health is influenced by multiple factors : oncology treatments received, self-esteem, body image, anxiety, depression, professional activity

Interventions

6 self-administered questionnaires (EORTC-QLQ-C30, RSE, BIS, HAD, FSFI, DAS-4) completed by the patients at every usual follow-up consultation. 1 (FSFI) or 2 (MSHQ, PEP) self-administered questionnaires completed by the partner (respectively female or male) between every usual follow-up consultation. Follow-up usual consultations : * T0 (at inclusion) : before disease + since diagnosis * C4 (chemotherapy course n°4) * C6 (chemotherapy course n°6) * M3 (3 months after chemotherapy) * M6 (6 months after chemotherapy) * A1 (1 year after chemotherapy) * A2 (2 years after chemotherapy)

Sponsors

University Hospital, Lille
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Female from 18 years * In a relationship with a man or a woman * Developing invasive carcinoma of breast cancer * Planned medical therapy project by chemotherapy * Followed up in the Observatory of fertility * Patient who gave written consent to participate in the study * Insured Social Patient * Patient willing to follow all study procedures and duration

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frameDescription
variation of score FSFI (female sexual function index)At 1 year after the start of chemotherapyThe FSFI score assesses female sexual functioning over the past four weeks. It is a self-evaluation by questionnaire. It consists of 19 questions with 5 or 6 possible answers per question, scored respectively from 1 to 5 and from 0 To evaluate, in women with non-metallic breast cancer followed in the Fertility Observatory at the Jeanne de Flandre Hospital, 1-year sexual health progression from chemotherapy initiation to sexual health assessment prior to cancer diagnosis announcement.

Secondary

MeasureTime frameDescription
association between psychometric factors assessed prior to cancer diagnosis and sexual health progression at 1 year of chemotherapy initiationAt inclusion, at 1 year and 2 years after chemotherapy
correlation between quality of life and psychometric factors and the assessment of sexual health of patients measured at all times.At inclusion, at 1 year and 2 years after chemotherapy
evolution of quality of life and psychometric factors at 1 year from the start of chemotherapy compared to the evaluation of these factors before the cancer diagnosis is announced.At inclusion, at 1 year and 2 years after chemotherapy
describe partners' sexual health by PEP (man)/FSFI (woman) during follow-upAt inclusion, at chemotherapy course n°4, at chemotherapy course n°6, at 3 months and at 6 months after chemotherapy, at 1 year and 2 years after chemotherapy,The PEP (Premature ejaculation profile) score explores premature ejaculation by self-questionnaire. It consists of 4 questions scored from 1 to 5. A high score corresponds to good male sexual health. A low score indicates premature ejaculation with repercussions on male sexual health.
testimony of patients expressing their experience of follow-up in the Fertility ObservatoryAt inclusion, at chemotherapy course n°4, at chemotherapy course n°6, at 3 months and at 6 months after chemotherapy, at 1 year and 2 years after chemotherapy,
describe partners' sexual health by MSHQ (man)/FSFI (woman) during follow-upAt inclusion, at chemotherapy course n°4, at chemotherapy course n°6, at 3 months and at 6 months after chemotherapy, at 1 year and 2 years after chemotherapy,MSHQ (Male Sexual Health Questionnaire) consists of 25 questions. It is a self-evaluation by the partner. A total score out of 125 is calculated. A high score corresponds to a good quality of male sexual life.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026